GlassScriptPhysician profile
Christopher Alan Zagar
NPI 1235127051
$22,443.01
in general payments reported to CMS, 2019-2025
20 companies · $8,089 in 2025
The $8,089 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.52 · 2020: $334 · 2021: $356 · 2022: $405 · 2023: $1,320 · 2024: $12K · 2025: $8,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,758 · Travel and Lodging: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,250.00 |
| Food and Beverage | $3,757.71 |
| Travel and Lodging | $281.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19,060.96 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,820.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $701.34 | 2020-2025 | Evenity, Prolia |
| Lilly USA, LLC | $173.85 | 2019-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $110.76 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $100.84 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.79 | 2019-2021 | |
| Abbott Laboratories | $62.00 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $58.28 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Shield Therapeutics INC | $50.62 | 2024-2025 | |
| Abbvie INC. | $39.34 | 2025 | |
| Dexcom, INC. | $29.66 | 2021 | |
| Paratek Pharmaceuticals, INC. | $29.42 | 2021-2022 | |
| Phadia US INC. | $24.26 | 2022 | |
| Janssen Scientific Affairs, LLC | $15.35 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $14.51 | 2020 | |
| Coopersurgical, INC. | $13.55 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.98 | 2019 | |
| Gilead Sciences, INC. | $12.97 | 2021 | |
| Merck Sharp & Dohme LLC | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Zagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.